Oztürk A, Günay A, Uskent N
Department of Haematology-Oncology, Haydarpaşa Training Hospital, Gülhane Military Medical Academy, Istanbul, Turkey.
Acta Haematol. 1998;99(2):89-91. doi: 10.1159/000040817.
The therapeutic efficacy of recombinant interferon-alpha (rIFN-alpha) has been evaluated in 7 patients with polycythaemia vera (PV), diagnosed according to the criteria of the Polycythemia Vera Study Group. Six complete responses and one partial response were achieved. Pruritus significantly improved in 80% (4/5) of the cases. Recombinant interferon-alpha had to be discontinued in 1 patient because of grade 3-4 nephrotoxicity according to WHO criteria. rIFN-alpha therapy significantly decreased the phlebotomy requirements and improved the mean corpuscular volume, erythrocyte and platelet counts, pruritus complaints and the degree of splenomegaly (p < 0.05). rIFN-alpha seems to be an effective treatment modality for the myeloproliferation of PV and pruritus complaints.
根据真性红细胞增多症研究组的标准，对7例真性红细胞增多症（PV）患者评估了重组α干扰素（rIFN-α）的治疗效果。获得了6例完全缓解和1例部分缓解。80%（4/5）的病例瘙痒症状明显改善。1例患者因符合世界卫生组织标准的3-4级肾毒性而不得不停用重组α干扰素。rIFN-α治疗显著减少了放血需求，并改善了平均红细胞体积、红细胞和血小板计数、瘙痒症状以及脾肿大程度（p<0.05）。rIFN-α似乎是治疗PV骨髓增殖和瘙痒症状的有效治疗方式。
